Breathe Well Live Well
|
AstraZeneca Set To Gain From New Asthma Drug
Seeking Alpha AstraZeneca and Rigel Pharmaceuticals (RIGL) have agreed to work together on a chronic asthma drug. The drug in question is R256, which is Rigel's "inhaled … |
View full post on asthma – Google News
|
AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
Genetic Engineering News Drug firm will start first-in-man studies and carry out clinical development program for R256. |
View full post on asthma – Google News
|
Rigel, AstraZeneca strike potential $100M asthma drug deal
Bizjournals.com (blog) AstraZeneca will license an experimental asthma treatment from South San Francisco's… |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
AstraZeneca to join Rigel in asthma drug venture
The News Journal AstraZeneca will join with Rigel Pharmaceutical Inc. to develop a treatment for chronic asthma that could be worth $100 million, if the drug can manage the … AstraZeneca partners with Rigel on asthma drug AstraZeneca and Rigel strike asthma deal worth up to $100M AstraZeneca And Rigel Sign Worldwide License Agreement For A … |
View full post on asthma – Google News
|
AstraZeneca partners with Rigel on asthma drug
CBS News NEW YORK — Rigel Pharmaceuticals Inc. plans to work with AstraZeneca PLC to develop an experimental asthma drug as part of a deal that could be worth … AstraZeneca and Rigel strike asthma deal worth up to $100M AstraZeneca And Rigel Sign Worldwide License Agreement For A … AstraZeneca, Rigel to Develop Asthma Treatment |
View full post on asthma – Google News
|
AstraZeneca and Rigel strike asthma deal worth up to $100M
FierceBiotech The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma. AstraZeneca And Rigel Sign Worldwide License Agreement For A … AstraZeneca, Rigel to Develop Asthma Treatment Rigel, AstraZeneca strike potential $100M asthma drug deal |
View full post on asthma – Google News
|
AstraZeneca And Rigel Sign Worldwide License Agreement For A …
MarketWatch (press release) "R256 emerged from Rigel's comprehensive study of chronic and severe asthma and lung inflammation. With AstraZeneca as our development partner, severely … |
View full post on asthma – Google News
|
AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma
Pharmaceutical Business Review AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma. SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
Healthcare Global (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News
 Financial Times |
AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug
The Pharma Letter Separately, Dynavax Technologies (Nasdaq: DVAX) and AstraZeneca yesterday announced their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Investigational New Drug-enabling preclinical toxicology studies. … The Market Just Spanked My Stock! |
View full post on asthma – Google News